Antitumor activity of Pulsatilla koreana extract in anaplastic thyroid cancer via apoptosis and anti-angiogenesis

Molecular Medicine Reports

Volumn 7, Issue 1, 2013, Pages 26-30

  Park, Byung Hee ^a   Jung, Kyung Hee ^a   Son, Mi Kwon ^a   Seo, Ju Hyeon ^a   Lee, Hee Seung ^a   Lee, Ju Hee ^a   Hong, Soon Sun ^a  

^a Inha University School of Medicine   (South Korea)

Author keywords

Anaplastic thyroid cancer; Angiogenesis; Apoptosis; Pulsatilla koreana extract; Thyroid cancer

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ANTINEOPLASTIC AGENT; CASPASE 3; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PLANT EXTRACT; PULSATILLA KOREANA EXTRACT; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANAPLASTIC THYROID CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DNA FRAGMENTATION; DOSE RESPONSE; DRUG SCREENING; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; MIGRATION INHIBITION; MOUSE; NICK END LABELING; NONHUMAN; PROTEIN EXPRESSION; PULSATILLA; PULSATILLA KOREANA; UMBILICAL VEIN ENDOTHELIAL CELL;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MALE; MICE; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; PULSATILLA; THYROID NEOPLASMS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84873855214     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1166     Document Type: Article

References (20)

1. Catalano MG, Poli R, Pugliese M, Fortunati N and Boccuzzi G: Emerging molecular therapies of advanced thyroid cancer. Mol Aspects Med 31: 215-226, 2010.
2. Fassnacht M, Kreissl MC, Weismann D and Allolio B: New targets and therapeutic approaches for endocrine malignancies. Pharmacol Ther 123: 117-141, 2009.
3. Patel KN and Shaha AR: Poorly differentiated and anaplastic thyroid cancer. Cancer Control 13: 119-128, 2006.
4. Sakorafas GH, Sampanis D and Safioleas M: Cervical lymph node dissection in papillary thyroid cancer: current trends, persisting controversies, and unclarified uncertainties. Surg Oncol 19: e57-e70, 2010.
5. Shimaoka K, Schoenfeld DA, DeWys WD, Creech RH and DeConti R: A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 56: 2155-2160, 1985.
6. Ahuja S and Ernst H: Chemotherapy of thyroid carcinoma. J Endocrinol Invest 10: 303-310, 1987.
7. Fleming ID, Phillips JL, Menck HR, Murphy GP and Winchester DP: The National Cancer Data Base report on recent hospital cancer program progress toward complete American Joint Committee on Cancer/TNM staging. Cancer 80: 2305-2310, 1997.
8. Herbst RS: ZD1839: targeting the epidermal growth factor receptor in cancer therapy. Expert Opin Investig Drugs 11: 837-849, 2002.
9. Bae K: The medicinal plants of Korea. Kyo-Hak Press, Seoul, 1999.
10. Lee HS, Beon MS and Kim MK: Selective growth inhibitor toward human intestinal bacteria derived from Pulsatilla cernua root. J Agric Food Chem 49: 4656-4661, 2001.
11. Bang SC, Lee JH, Song GY, Kim DH, Yoon MY and Ahn BZ: Antitumor activity of Pulsatillakoreana saponins and their structure-activity relationship. Chem Pharm Bull (Tokyo) 53: 1451-1454, 2005.
12. Hong SW, Jung KH, Lee HS, etal: Apoptotic and anti-angiogenic effects of Pulsatillakoreana extract on hepatocellular carcinoma. Int J Oncol 40: 452-460, 2012.
13. Yin F, Giuliano AE and Van Herle AJ: Growth inhibitory effects of flavonoids in human thyroid cancer cell lines. Thyroid 9: 369-376, 1999.
14. Cragg GM, Newman DJ and Yang SS: Natural product extracts of plant and marine origin having antileukemia potential. The NCI experience. J Nat Prod 69: 488-498, 2006.
15. O'Connor L, Huang DC, O'Reilly LA and Strasser A: Apoptosis and cell division. Curr Opin Cell Biol 12: 257-263, 2000.
16. Riedl SJ and Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol 5: 897-907, 2004.
17. Krishnakumar R and Kraus WL: The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 39: 8-24, 2010.
18. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990.
19. Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364, 1996.
20. Bolat F, Haberal N, Tunali N, Aslan E, Bal N and Tuncer I: Expression of vascular endothelial growth factor (VEGF), hypoxia inducible factor 1 alpha (HIF-1alpha), and transforming growth factors beta1 (TGFbeta1) and beta3 (TGFbeta3) in gestational trophoblastic disease. Pathol Res Pract 206: 19-23, 2010.